<DOC>
	<DOCNO>NCT01809132</DOCNO>
	<brief_summary>This study compare two different treatment acute alcoholic hepatitis . The current standard care treatment corticosteroid ( methylprednisolone ) . This compare treatment anakinra , pentoxifylline , plus zinc sulfate . The participant treat follow 6 month two treatment group compare difference death rate laboratory test measure liver gut function .</brief_summary>
	<brief_title>Efficacy Study Anakinra , Pentoxifylline , Zinc Compared Methylprednisolone Severe Acute Alcoholic Hepatitis</brief_title>
	<detailed_description>This study test hypothesis syndrome acute alcoholic hepatitis result severe inflammation dysregulated cytokine . Steroid monotherapy effective patient study utilize compound potential improve gut barrier function , reduce associate inflammation , prevent development hepatorenal syndrome organ failure . Patients randomize receive 28 day methylprednisolone 32 mg daily OR therapy include combination anakinra ( interleukin-1 receptor antagonist ) 100mg subcutaneous injection daily 14 day plus pentoxifylline 400 mg orally three time daily one month plus zinc supplement ( 220 mg zinc sulfate ) give orally 6 month . This combination strategy address acute inflammatory component disease ( anakinra ) protect development hepatorenal syndrome ( pentoxifylline ) , one frequent cause death severe acute alcoholic hepatitis , improve gut mucosal integrity ( zinc supplement ) . The primary outcome 6 month mortality rate . Secondary outcome measure 30 , 90 180 day . Individuals participate interventional arm trial receive standard care observe 6 month . They enrol baseline interval health information laboratory result collect .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Zinc Sulfate</mesh_term>
	<criteria>1 . Ability provide inform consent subject appropriate family member 2 . Age 2170 year 3 . Recent alcohol consumption &gt; 50 g/d &gt; 6 month , continue within two month enrollment 4. d. At least 2 follow symptom acute alcoholic hepatitis : Anorexia , nausea , RUQ pain 5 . Liver biopsy show alcoholic hepatitis ( steatohepatitis ) OR ultrasound liver show increased echogenicity OR CT scan showing decreased attenuation liver compare spleen OR MRI show fatty liver ( decreased signal intensity T1 weight image ) If liver biopsy confirm diagnosis alcoholic hepatitis requirement AST elevation &gt; 50 waive . The liver biopsy must do within 60 day study enrollment . 6 . AST level : AST &gt; Or equal 50 IU/mL less 500 IU/mL AST &gt; ALT , ratio AST/ALT &gt; 1.5 ; ALT &lt; 200 IU/mL biopsy proven alcoholic hepatitis . 7 . Model EndStage Liver Disease ( MELD ) ≥ 20 Maddrey DF ≥ 32 . 8 . Willingness utilize two reliable form contraception ( male females childbearing potential ) screen first 6 week study . 1 . Hypotension BP &lt; 80/50 volume repletion 2 . Pregnancy ; incarceration ; inability provide consent lack appropriate family member 3 . Signs uncontrolled systemic infection : Fever &gt; 38°C positive blood ascites culture appropriate antibiotic therapy ≥ 3 day within 3 day inclusion 4 . Acute gastrointestinal bleeding require &gt; 2 unit blood transfusion within previous 4 day 5 . Undue risk immunosuppression : Positive HBsAg ; positive skin PPD skin test , positive quantiferon , history treatment tuberculosis ; history malignancy except skin cancer include hepatocellular carcinoma within last five year ; HIV infection 6 . Recent previous treatment corticosteroid immunosuppressive medication include specific antiTNF therapy ( include pentoxifylline ) , calcineurin inhibitor within previous 3 month . Treatment corticosteroid ≤3 day prior baseline acceptable . 7 . Evidence acute pancreatitis : CT evidence amylase lipase &gt; 5 X upper limit normal ( ULN ) . 8 . Serious cardiac , respiratory neurologic disease evidence liver diseases autoimmune hepatitis , primary biliary cirrhosis , primary sclerosing cholangitis , Wilson disease , hemochromatosis , secondary iron overload due chronic hemolysis , alpha1antitrypsin deficiency 9 . Acute chronic kidney injury serum creatinine &gt; 3.0 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis , alcoholic</keyword>
	<keyword>pentoxifylline</keyword>
	<keyword>zinc</keyword>
	<keyword>anakinra</keyword>
	<keyword>glucocorticoid</keyword>
	<keyword>MELD score</keyword>
	<keyword>Intestinal mucosa</keyword>
</DOC>